Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas  [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]).

Source: European Journal of Cancer - September 11, 2019 Category: Cancer & Oncology Authors: Robin L. Jones, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles Rudin, Michael Sawyer, David Khayat, Ahmad Awada, Judith M.P.G.M. de Vos-Geelen, T.R. Jeffry Evans, Jennifer Obel, Bruce Brockstein, Jac Tags: Original Research Source Type: research